In Utero Tenofovir Exposure Shows No Effect on Infant Bone Health

The findings of a new cross-sectional study are somewhat reassuring but require validation.

Tenofovir is widely used in the treatment of HIV-infected pregnant women because of its tolerability. However, current U.S. guidelines cite AZT/3TC as the preferred nucleoside backbone for pregnant women, in part because of concerns about potential fetal bone toxicity with tenofovir. These concerns stem from animal studies, as well as limited human surveillance data showing marginal signals of bone and growth problems in children receiving long-term tenofovir.

In the present, multicenter, cross-sectional study, researchers evaluated bone and growth characteristics among 68 HIV-negative children who were exposed to antiretrovirals in utero; 33 had been exposed to tenofovir, and 35 had not. The median age at the time of evaluation was 23 month…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

In Utero Tenofovir Exposure Shows No Effect on Infant Bone Health

Topics

Reviewing Author